scholarly article | Q13442814 |
P50 | author | Jean Popovici | Q54438232 |
Marcelo U. Ferreira | Q55033395 | ||
Sebastien Dechavanne | Q61099536 | ||
Samantha J Barnes | Q89705262 | ||
Edwin Chen | Q92827820 | ||
Seila Suon | Q114064044 | ||
Sokunthea Sreng | Q114064053 | ||
Chanaki Amaratunga | Q28035108 | ||
John H. Adams | Q47150509 | ||
P2093 | author name string | Niraj H Tolia | |
Benoit Witkowski | |||
Rick M Fairhurst | |||
Christopher L King | |||
Lenore L Carias | |||
Camille Roesch | |||
Vanessa C Nicolete | |||
Celia Dechavanne | |||
P2860 | cites work | A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein. | Q53700367 |
A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum. | Q54216698 | ||
Antihomotypic affinity maturation improves human B cell responses against a repetitive epitope | Q56376231 | ||
Genetic diversity in two Plasmodium vivax protein ligands for reticulocyte invasion | Q57805338 | ||
The sequence manipulation suite: JavaScript programs for analyzing and formatting protein and DNA sequences | Q73927391 | ||
IMGT/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences | Q84245408 | ||
Red blood cell invasion by Plasmodium vivax: structural basis for DBP engagement of DARC | Q21131367 | ||
The Resistance Factor to Plasmodium vivax in Blacks | Q22250916 | ||
Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people | Q24600330 | ||
Changes in malaria burden and transmission in sentinel sites after the roll-out of long-lasting insecticidal nets in Papua New Guinea | Q26315315 | ||
The Duffy binding protein as a key target for a Plasmodium vivax vaccine: lessons from the Brazilian Amazon | Q27009149 | ||
Broadly neutralizing antibodies against influenza virus and prospects for universal therapies | Q27010503 | ||
Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus | Q27473186 | ||
Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors | Q27643993 | ||
Dimerization of Plasmodium vivax DBP is induced upon receptor binding and drives recognition of DARC | Q27670749 | ||
Plasmodium vivax vaccine research - we've only just begun | Q28079136 | ||
The Presence, Persistence and Functional Properties of Plasmodium vivax Duffy Binding Protein II Antibodies Are Influenced by HLA Class II Allelic Variants | Q28396379 | ||
Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein | Q28471832 | ||
Structural analysis of the synthetic Duffy Binding Protein (DBP) antigen DEKnull relevant for Plasmodium vivax malaria vaccine design | Q28544738 | ||
Global Epidemiology of Plasmodium vivax | Q30249044 | ||
Isolation of a monoclonal antibody from a malaria patient-derived phage display library recognising the Block 2 region of Plasmodium falciparum merozoite surface protein-1. | Q30651257 | ||
Recombinant human antibodies specific for the Pfs48/45 protein of the malaria parasite Plasmodium falciparum | Q30984883 | ||
A family of erythrocyte binding proteins of malaria parasites | Q33198214 | ||
Human recombinant antibodies against Plasmodium falciparum merozoite surface protein 3 cloned from peripheral blood leukocytes of individuals with immunity to malaria demonstrate antiparasitic properties | Q33244194 | ||
Production of high-affinity human monoclonal antibody fab fragments to the 19-kilodalton C-terminal merozoite surface protein 1 of Plasmodium falciparum | Q33282524 | ||
Single-chain antibody fragment specific for Plasmodium vivax Duffy binding protein | Q33282823 | ||
Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children | Q33530114 | ||
Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies. | Q33798074 | ||
Fy(a)/Fy(b) antigen polymorphism in human erythrocyte Duffy antigen affects susceptibility to Plasmodium vivax malaria | Q34236565 | ||
Characterization of inhibitory anti-Duffy binding protein II immunity: approach to Plasmodium vivax vaccine development in Thailand | Q34256740 | ||
Immunogenicity of a synthetic vaccine based on Plasmodium vivax Duffy binding protein region II. | Q34260750 | ||
Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion | Q34331219 | ||
HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. | Q34527469 | ||
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption | Q34531858 | ||
Natural variation within the principal adhesion domain of the Plasmodium vivax duffy binding protein | Q34548865 | ||
The most polymorphic residue on Plasmodium falciparum apical membrane antigen 1 determines binding of an invasion-inhibitory antibody | Q34601904 | ||
Ex vivo characterization and isolation of rare memory B cells with antigen tetramers | Q35112237 | ||
Submicroscopic and asymptomatic Plasmodium falciparum and Plasmodium vivax infections are common in western Thailand - molecular and serological evidence | Q35128307 | ||
Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort | Q35894094 | ||
Biosignatures of Exposure/Transmission and Immunity | Q36071335 | ||
Independent Origin and Global Distribution of Distinct Plasmodium vivax Duffy Binding Protein Gene Duplications | Q36178527 | ||
Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies | Q36208191 | ||
The domain on the Duffy blood group antigen for binding Plasmodium vivax and P. knowlesi malarial parasites to erythrocytes | Q36367429 | ||
Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning | Q36459907 | ||
Towards HIV-1 remission: potential roles for broadly neutralizing antibodies | Q36515149 | ||
Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection | Q36751523 | ||
Higher microsatellite diversity in Plasmodium vivax than in sympatric Plasmodium falciparum populations in Pursat, Western Cambodia | Q36952727 | ||
Broadly neutralizing epitopes in the Plasmodium vivax vaccine candidate Duffy Binding Protein | Q36978206 | ||
Strain-specific duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous plasmodium vivax strains in Papua New Guinean children | Q37333369 | ||
Human pregnancy-associated malaria-specific B cells target polymorphic, conformational epitopes in VAR2CSA | Q37426131 | ||
Characterization of a novel inhibitory human monoclonal antibody directed against Plasmodium falciparum Apical Membrane Antigen 1. | Q37522507 | ||
Invasion-inhibitory antibodies elicited by immunization with Plasmodium vivax apical membrane antigen-1 expressed in Pichia pastoris yeast | Q37643896 | ||
Prevention of Respiratory Syncytial Virus Infection: From Vaccine to Antibody | Q38535730 | ||
Expression cloning of human B cell immunoglobulins | Q39214732 | ||
The Immunoregulatory Roles of Antibody Glycosylation | Q39225081 | ||
Epitope-specific humoral immunity to Plasmodium vivax Duffy binding protein. | Q39746136 | ||
Improved light microscopy counting method for accurately counting Plasmodium parasitemia and reticulocytemia | Q40716448 | ||
Isolation, production and characterization of fully human monoclonal antibodies directed to Plasmodium falciparum MSP10. | Q41587442 | ||
Antibody-specific model of amino acid substitution for immunological inferences from alignments of antibody sequences | Q41657201 | ||
Strain-transcending Fc-dependent killing of Plasmodium falciparum by merozoite surface protein 2 allele-specific human antibodies | Q42102268 | ||
Atypical and classical memory B cells produce Plasmodium falciparum neutralizing antibodies. | Q43245288 | ||
Naturally Acquired Binding-Inhibitory Antibodies to Plasmodium vivax Duffy Binding Protein and Clinical Immunity to Malaria in Rural Amazonians. | Q46926980 | ||
An engineered vaccine of the Plasmodium vivax Duffy binding protein enhances induction of broadly neutralizing antibodies | Q47150417 | ||
Structural basis for antibody recognition of the NANP repeats in Plasmodium falciparum circumsporozoite protein | Q47161602 | ||
Transferrin receptor 1 is a reticulocyte-specific receptor for Plasmodium vivax. | Q47208042 | ||
Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system | Q47756393 | ||
Rationale for development of a synthetic vaccine against plasmodium falciparum malaria | Q47886490 | ||
Enhanced ex vivo Plasmodium vivax intraerythrocytic enrichment and maturation for rapid and sensitive parasite growth assays | Q48023790 | ||
Clonal selection drives protective memory B cell responses in controlled human malaria infection | Q49913937 | ||
A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. | Q52350559 | ||
P433 | issue | 9 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Plasmodium vivax | Q311376 |
P304 | page(s) | 2648-2660 | |
P577 | publication date | 2019-04-03 | |
P1433 | published in | Journal of Immunology | Q3521441 |
P1476 | title | Identification and Characterization of Functional Human Monoclonal Antibodies to Plasmodium vivax Duffy-Binding Protein | |
P478 | volume | 202 |